Evidence map›Paper›PMID 35904209›Full record

ArticleJournal of the American Heart Association2022

Predictors and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients With a Left Ventricular Ejection Fraction Above or Below 60.

Akito Nakagawa, Yoshio Yasumura, Chikako Yoshida, Takahiro Okumura, Jun Tateishi, Junichi Yoshida, Masahiro Seo, Masamichi Yano, Takaharu Hayashi, Yusuke Nakagawa and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Akito NakagawaDivision of Cardiovascular Medicine Amagasaki-Chuo Hospital Amagasaki Hyogo Japan.ORCID 0000-0001-8276-1505
Yoshio YasumuraDivision of Cardiovascular Medicine Amagasaki-Chuo Hospital Amagasaki Hyogo Japan.
Chikako YoshidaDivision of Cardiovascular Medicine Amagasaki-Chuo Hospital Amagasaki Hyogo Japan.
Takahiro OkumuraDivision of Cardiovascular Medicine Amagasaki-Chuo Hospital Amagasaki Hyogo Japan.
Jun TateishiDivision of Cardiovascular Medicine Amagasaki-Chuo Hospital Amagasaki Hyogo Japan.
Junichi YoshidaDivision of Cardiovascular Medicine Amagasaki-Chuo Hospital Amagasaki Hyogo Japan.
Masahiro SeoDivision of Cardiology Osaka General Medical Center Osaka Osaka Japan.ORCID 0000-0001-6517-486X
Masamichi YanoDivision of Cardiology Osaka Rosai Hospital Sakai Osaka Japan.
Takaharu HayashiDivision of Cardiology Osaka Police Hospital Osaka Osaka Japan.ORCID 0000-0003-1637-4536
Yusuke NakagawaDivision of Cardiology Kawanishi City Hospital Kawanishi Hyogo Japan.
Shunsuke TamakiDepartment of Cardiology Rinku General Medical Center Izumisano Osaka Japan.ORCID 0000-0001-5642-3836
Takahisa YamadaDivision of Cardiology Osaka General Medical Center Osaka Osaka Japan.
Hiroyuki KurakamiDepartment of Medical Innovation Osaka University Hospital Suita Osaka Japan.
Yohei SotomiDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Osaka Japan.
Daisaku NakataniDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Osaka Japan.
Shungo HikosoDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Osaka Japan.ORCID 0000-0003-2284-1970
Yasushi SakataDepartment of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Osaka Japan.ORCID 0000-0002-5618-4721
Osaka CardioVascular Conference (OCVC)‐Heart Failure Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Although potential therapeutic candidates for heart failure with preserved ejection fraction (HFpEF) are emerging, it is still unclear whether they will be effective in patients with left ventricular ejection fraction (LVEF) of 60% or higher. Our aim was to identify the clinical characteristics of these patients with HFpEF by comparing them to patients with LVEF below 60%. Methods and Results From a multicenter, prospective, observational cohort (PURSUIT-HFpEF [Prospective Multicenter Obsevational Study of Patients with Heart Failure with Preserved Ejection Fraction]), we investigated 812 consecutive patients (median age, 83 years; 57% women), including 316 with 50% ≤ LVEF <60% and 496 with 60% ≤ LVEF, and compared the clinical backgrounds of the 2 groups and their prognoses for cardiac mortality or HF readmission. Two hundred four adverse outcomes occurred at a median of 366 days. Multivariable Cox regression tests adjusted for age, sex, heart rate, atrial fibrillation, estimated glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, and prior heart failure hospitalization revealed that systolic blood pressure (hazard ratio [HR], 0.925 [95% CI, 0.862-0.992];

Indexed as

Heart FailureVentricular Function, LeftAged, 80 and overFemaleHumansMalePrognosisProspective StudiesStroke Volumeheart failure with preserved ejection fractionleft ventricular ejection fractionprognostic factor

Identifiers

PMID35904209
PMCPMC9375469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.